We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Praxis Precision Medicines I
6 own
12 watching
Current Price
$0
$-0.04
(-3.3%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
61.44M
52-Week High
5.25
52-Week Low
0.79
Average Volume
0.37M
Dividend Yield
--
P/E Ratio
--
Market Capitalization61.44M52-Week High5.2552-Week Low0.79Average Volume0.37MDividend Yield--P/E Ratio--What does the Praxis Precision Medicines I do?
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Read More
How much money does Praxis Precision Medicines I make?
News & Events about Praxis Precision Medicines I.
Globe Newswire
2 months ago
BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, ...
Globe Newswire
3 months ago
Based upon observed efficacy and safety profile, Praxis intends to engage with the FDA in an end of Phase 2 meeting and initiate a ulixacaltamide Phase 3 study for the treatment of essential tremor in 2H23 Ulixacaltamide demonstrated improvement in modified Activities of Daily Living (mADL) primary ...
Ticker Report
3 months ago
Praxis Precision Medicines, Inc. (NASDAQ:PRAX Get Rating) Equities research analysts at William Blair issued their Q1 2024 earnings estimates for Praxis Precision Medicines in a note issued to investors on Tuesday, February 7th. William Blair analyst M. Minter anticipates that the ...
Globe Newswire
4 months ago
Ulixacaltamide (PRAX-944) Phase 2b Essential1 study topline results for essential tremor expected in 1Q23; Praxis to enter quiet period following market close on Thursday, February 9 Topline results expected for each of three clinical-stage epilepsy programs in 2023 PRAX-222 first-in-patient EMBRAVE...
Zolmax
4 months ago
Praxis Precision Medicines (NASDAQ:PRAX Get Rating) had its target price boosted by HC Wainwright from $10.00 to $16.00 in a report published on Friday, The Fly reports. The firm currently has a buy rating on the stock. Praxis Precision Medicines Stock Performance Shares of PRAX opened at $4.64 on ...
Frequently Asked Questions
Frequently Asked Questions
What is Praxis Precision Medicines I share price today?
Can Indians buy Praxis Precision Medicines I shares?
How can I buy Praxis Precision Medicines I shares from India?
Can Fractional shares of Praxis Precision Medicines I be purchased?
What are the documents required to start investing in Praxis Precision Medicines I stocks?
What is today’s traded volume of Praxis Precision Medicines I?
What is today’s market capitalisation of Praxis Precision Medicines I?
What is the 52-Week High and Low Range of Praxis Precision Medicines I?
What percentage is Praxis Precision Medicines I down from its 52-Week High?
What percentage is Praxis Precision Medicines I up from its 52-Week Low?
Current Price
$0
$-0.04
(-3.3%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.